The immune system must maintain a delicate balance to defend against harmful threats while avoiding excessive inflammation.

Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the immune system.

In a recent study published in the journal Nature Medicine, researchers examine clinical glioblastoma and benign intracranial samples to determine the presence and function of immune cells in the ...

AC Immune SA (NASDAQ:ACIU) revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease. Dr. Andrea Pfeifer ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

AC Immune (ACIU) to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the ...

AC Immune (ACIU) and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global ...

Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations 100% of patients receiving ACI-7104.056 responded ...

A human fetus in its second trimester is extraordinarily busy. It is developing skin and bones, the ability to hear and swallow, and working on its first bowel movement. Now, a study published on 14 ...

− Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression − AC Immune to ...

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high ...